A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians

Background. A safe, affordable, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) was developed to control epidemic group A meningitis in Africa. Documentation of the safety specifications of the PsA-TT vaccine was warranted, with sufficient exposure to detect potential r...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Infect Dis
Asıl Yazarlar: Tapia, Milagritos D., Sow, Samba O., Haidara, Fadima Cheick, Diallo, Fatoumata, Doumbia, Moussa, Enwere, Godwin C., Paranjape, Gandhali, Hervé, Jacques, Bouma, Enricke, Parulekar, Varsha, Martellet, Lionel, Chaumont, Julie, Plikaytis, Brian D., Tang, Yuxiao, Kulkarni, Prasad S., Hartmann, Katharina, Preziosi, Marie-Pierre
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2015
Konular:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639507/
https://ncbi.nlm.nih.gov/pubmed/26553682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/civ626
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller